Regeneron Pharmaceuticals REGN Insider Ownership

NASDAQ REGN

$790.74 -5.60 (-0.70%)

At close: Oct 16, 2026 · 4:00 PM EDT

Insider Holdings by Owner

936.61K Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

0.783%

▲+0.0043% pp QoQ

Shares Held by Insiders

1.08Mn

filed for Sep 2026

▲+0.56% QoQ

Shares Outstanding

138.00Mn

138,000,000 shares

Direct Holdings

784.99K

Indirect: 296.08K

Net Shares Traded (QoQ)

+5.99K

net buying in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 11, 2026

Over the trailing 12 months, REGN insiders sold $12.91 million worth of shares (17.41K shares) in open-market trades, with no open-market purchases.

Counted by insider, open-market selling of REGN stock in the past 12 months came from 7 insiders, with no insider buying.
Christine A. Poon (Director) was the top open-market seller of Regeneron Pharmaceuticals over the past 12 months, with $4.25 million sold (6.5K shares) and the latest sale on October 29, 2025.
Marion McCourt (EVP Commercial) made the most recent open-market trade by an insider of Regeneron Pharmaceuticals, a sale of 1.13K shares for $969,708 on September 3, 2026.
Apart from open-market trades, REGN insiders received 11.44K shares in stock awards, acquired 441.05K shares through option exercises and conversions, gave up 396.69K shares to cover taxes or exercise prices and gave away 1.54K shares as gifts in the past 12 months.
Per Business Quant data, Regeneron Pharmaceuticals insiders hold 1.08Mn shares in total based on their latest Form 4 filings, up 0.56% from 1.08Mn shares at the end of Q2 2026.
By type of ownership, REGN insiders hold 72.61% of their shares directly (784.99K shares) and 27.39% indirectly (296.08K shares).
REGN's insider total is spread across 20 insiders who have filed a Form 4 in the past two years.
REGN's three largest insider shareholders, per their latest Form 4 filings, are George Yancopoulos (Board Co Chair, President & CSO, 546.51K shares), Leonard S. Schleifer (Board Co Chair, President & CEO, 254.51K shares) and Neil Stahl (EVP Research and Development, 53.43K shares).
The holding of George Yancopoulos makes up 50.55% of all shares held by Regeneron Pharmaceuticals insiders.
Institutional holders reported 66.16% of Regeneron Pharmaceuticals' outstanding shares for Q2 2026; insiders' latest Form 4 filings put their stake at about 0.78%, and other investors, including the public, hold the remaining 33.06%.
A total of 44 Form 4 filings with transactions in Regeneron Pharmaceuticals stock were made over the past 12 months, by 19 insiders.
This summary of Regeneron Pharmaceuticals insider activity covers Form 4 filings through September 3, 2026.

Form 4 Holdings

Insiders Holding REGN

Insiders 23

Shares held 936.61K

Of outstanding 0.679%

#	Insider	Position	Direct	Indirect	Total	Share of Insiders	Last Filed
1	George Yancopoulos	Bd. Co Chair, President Cso	310,460	0	310,460	33.1%	05 Jan, 2026
2	Leonard S Schleifer	Bd. Co Chair, President Ceo	214,523	0	214,523	22.9%	05 Jan, 2026
3	P Roy Vagelos	Chairman Of The Board	0	125,493	125,493	13.4%	05 Apr, 2023
4	Neil Stahl	Evp Research And Development	48,829	0	48,829	5.2%	18 Dec, 2024
5	Andrew J Murphy	Co Chief Scientific Officer	47,833	0	47,833	5.1%	15 Oct, 2026
6	Joseph J Larosa	Evp General Counsel And Secret	36,373	0	36,373	3.9%	21 Aug, 2026
7	George L Sing	Director	31,007	0	31,007	3.3%	06 Jan, 2026
8	Robert E Landry	Evp Finance Cfo	23,693	0	23,693	2.5%	06 Feb, 2024
9	Plew Daniel P Van	Evp General Mgr, Industrial	21,673	0	21,673	2.3%	11 Dec, 2025
10	Christopher R. Fenimore	Evp Finance Cfo	19,984	0	19,984	2.1%	20 Aug, 2026
11	Arthur F Ryan	Director	17,303	0	17,303	1.8%	07 Jul, 2026
12	Marion Mccourt	Evp Commercial	12,003	0	12,003	1.3%	03 Sep, 2026
13	Joseph L Goldstein	Director	6,703	0	6,703	0.7%	06 Jan, 2026
14	Christine A Poon	Director	5,219	0	5,219	0.6%	06 Jan, 2026
15	Jason Pitofsky	Svp Controller	4,272	0	4,272	0.5%	11 Feb, 2026
16	Marc Tessier-Lavigne	Director	2,434	0	2,434	0.3%	05 Jan, 2023
17	N Anthony Coles	Director	1,714	0	1,714	0.2%	06 Jan, 2026
18	Huda Y Zoghbi	Director	1,703	0	1,703	0.2%	12 Aug, 2026
19	Bonnie L Bassler	Director	1,703	0	1,703	0.2%	08 Jan, 2026
20	Michael S Brown	Director	1,703	0	1,703	0.2%	06 Jan, 2026
21	Craig B. Thompson	Director	775	0	775	0.1%	06 Jan, 2026
22	Kathryn Guarini	Director	603	0	603	0.1%	03 Sep, 2026
23	David P Schenkein	Director	603	0	603	0.1%	06 Jan, 2026

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

8,195 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
13 Oct, 2026	Andrew J Murphy	Co Chief Scientific Officer	Acquired M	17,000	$381.92	$6.49Mn	64,833	Direct
13 Oct, 2026	Andrew J Murphy	Co Chief Scientific Officer	Disposed F	12,853	$754.58	$9.70Mn	51,980	Direct
14 Oct, 2026	Andrew J Murphy	Co Chief Scientific Officer	Disposed S	6	$753.76	$4.52K	51,974	Direct
14 Oct, 2026	Andrew J Murphy	Co Chief Scientific Officer	Disposed S	35	$755.91	$26.46K	51,939	Direct
14 Oct, 2026	Andrew J Murphy	Co Chief Scientific Officer	Disposed S	16	$757.68	$12.12K	51,923	Direct
14 Oct, 2026	Andrew J Murphy	Co Chief Scientific Officer	Disposed S	24	$758.16	$18.20K	51,899	Direct
14 Oct, 2026	Andrew J Murphy	Co Chief Scientific Officer	Disposed S	14	$759.96	$10.64K	51,885	Direct
14 Oct, 2026	Andrew J Murphy	Co Chief Scientific Officer	Disposed S	74	$760.65	$56.29K	51,811	Direct
14 Oct, 2026	Andrew J Murphy	Co Chief Scientific Officer	Disposed S	27	$761.36	$20.56K	51,784	Direct
14 Oct, 2026	Andrew J Murphy	Co Chief Scientific Officer	Disposed S	55	$762.57	$41.94K	51,729	Direct
14 Oct, 2026	Andrew J Murphy	Co Chief Scientific Officer	Disposed S	25	$763.76	$19.09K	51,704	Direct
14 Oct, 2026	Andrew J Murphy	Co Chief Scientific Officer	Disposed S	219	$764.40	$167.40K	51,485	Direct
14 Oct, 2026	Andrew J Murphy	Co Chief Scientific Officer	Disposed S	271	$765.39	$207.42K	51,214	Direct
14 Oct, 2026	Andrew J Murphy	Co Chief Scientific Officer	Disposed S	279	$766.47	$213.85K	50,935	Direct
14 Oct, 2026	Andrew J Murphy	Co Chief Scientific Officer	Disposed S	192	$767.39	$147.34K	50,743	Direct
14 Oct, 2026	Andrew J Murphy	Co Chief Scientific Officer	Disposed S	105	$768.33	$80.67K	50,638	Direct
14 Oct, 2026	Andrew J Murphy	Co Chief Scientific Officer	Disposed S	127	$769.30	$97.70K	50,511	Direct
14 Oct, 2026	Andrew J Murphy	Co Chief Scientific Officer	Disposed S	12	$770.20	$9.24K	50,499	Direct
14 Oct, 2026	Andrew J Murphy	Co Chief Scientific Officer	Disposed S	283	$771.56	$218.35K	50,216	Direct
14 Oct, 2026	Andrew J Murphy	Co Chief Scientific Officer	Disposed S	211	$772.56	$163.01K	50,005	Direct

Showing 1 to 20 of 8,195 transactions